Table 4.

Factors associated with the selection of an individual NOAC over another NOAC for stroke prevention in patients with AF, assessed using multivariable logistic regression models (participating centers were included as potential confounders).

Factors	Apixaban			Dabigatran			Rivaroxaban
	OR	95%CI	p	OR	95%CI	p	OR	95%CI	p
Age (per 5 years)	1.14	1.09–1.19	<0.0001	0.95	0.91–0.99	0.0112	0.94	0.90–0.97	0.0009
Heart failure	1.38	1.14–1.67	0.001	0.84	0.70–1.03	0.0916	0.86	0.72–1.03	0.0958
Vascular disease	1.03	0.86–1.24	0.7241	1.20	0.99–1.45	0.0523	0.84	0.70–0.99	0.0464
Female	1.09	0.92–1.29	0.3223	0.8	0.67–0.96	0.0139	1.11	0.94–1.31	0.2033
Non-permanent AF	0.91	0.74–1.10	0.3319	1.03	0.83–1.27	0.812	1.09	0.90–1.33	0.3706
Malignancy	1.38	0.95–2.00	0.09	0.83	0.54–1.26	0.3737	0.86	0.59–1.26	0.4471
Any previous bleeding	2.37	1.67–3.38	<0.0001	0.86	0.57–1.28	0.4589	0.43	0.28–0.64	<0.0001
eGFR < 60 mL/min/1.73m2	1.38	1.15–1.64	0.0004	0.79	0.66–0.95	0.0108	0.91	0.77–1.08	0.2871
Antiplatelets with NOAC	1.19	0.91–1.55	0.1904	0.76	0.57–1.01	0.0564	1.08	0.84–1.39	0.5473

Abbreviation: AF, atrial fibrillation; CI, confidence interval; eGFR, estimated glomerular filtration rate; NOAC, non-vitamin K antagonist oral anticoagulant; OR, odds ratio.